Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

prescription medicines

- PMLiVE

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack

AstraZeneca AZ

AstraZeneca shaken by FDA partial hold on durvalumab trial

Aims to resume trial recruitment as soon as possible after bleeding side effects curb study

- PMLiVE

GSK’s Bexsero vaccine growing fast, despite “tight” supply

Meningitis drug’s sales double as third quarter results exceed expectations

- PMLiVE

Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology

- PMLiVE

GSK’s blockbuster hopeful Shingrix filed in US

Clinical data showed shingles vaccine had 90% efficacy in elderly patients

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

- PMLiVE

Pharma Perspectives: The agency selection process (part 2)

AstraZeneca's Samuel Hollis on the evolution of the agency selection process

- PMLiVE

Rigel shaken after fostamatinib misses phase III trial target

Firm will still pursue early 2017 FDA approval for the autoimmune disease therapy

- PMLiVE

Synairgen sinks as AZ halts trial of asthma drug

Results from a phase II trial of inhaled antiviral therapy set to be inconclusive

- PMLiVE

Tesaro’s niraparib threatens Lynparza after acing ovarian cancer trial

Maintenance therapy significantly improved progression-free survival regardless of BRCA status

- PMLiVE

Call for better patient-focused information in cancer

PatientView survey highlights shortcomings in explaining newer science

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links